A Prospective Observational Safety Study in Patients With Advanced Prostate Cancer Treated With Firmagon (Degarelix) on a GnRH Agonist

Trial Profile

A Prospective Observational Safety Study in Patients With Advanced Prostate Cancer Treated With Firmagon (Degarelix) on a GnRH Agonist

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Degarelix (Primary) ; LHRH receptor agonists
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 28 Jan 2015 Planned End Date changed from 1 Dec 2017 to 1 May 2018 according to ClinicalTrials.gov record.
    • 22 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Aug 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004100).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top